Martindale Pharma acquires Viridian Pharma

Specialty drugmaker Martindale Pharma says it has completed the acquisition of Viridian Pharma, a fellow UK-based developer and supplier of niche pharmaceutical products. Although financial terms were not disclosed, the acquisition will be immediately accretive to earnings, the company stated.

This acquisition is part of Martindale Pharma’s strategy to expand its product portfolio and actively support further growth of its hospital-initiated medicines product range.

Viridian Pharma has developed five products, all of which have regulatory approval in the UK and represent first-to-market specialty hospital-prescribed medicines. The product portfolio consists of caffeine citrate injection and caffeine citrate oral solution for apnea of prematurity in pre-term babies, sodium chloride oral solution for correction of hypernatremia in infants, sodium citrate oral solution for the prevention of respiratory complications in women undergoing caesarean sections and peppermint water for symptomatic relief of minor upper digestive complaints.